Last updated: August 3, 2025
Introduction
Denmark Patent DK2376075, titled "Pharmaceutical Composition," pertains to innovations in drug formulation, likely aiming at improving stability, bioavailability, or targeted delivery. As a key asset within the pharmaceutical patent landscape, understanding its scope and claims is essential for stakeholders analyzing competitive positioning, licensing opportunities, or patent strategy. This report provides an in-depth examination of the patent's scope, claims, and its position within the broader patent landscape.
Overview of DK2376075
Patent DK2376075 was granted by the Danish Patent and Trademark Office (DKPTO). The patent's priority date is critical for establishing novelty—although not specified here, typically these patents date back to the early 2010s. It covers a pharmaceutical composition with specific formulations, possibly involving active pharmaceutical ingredients (APIs), excipients, or delivery systems.
Scope of the Patent
The scope of DK2376075 encompasses a novel pharmaceutical composition defined by specific features claimed in the patent. Critical parameters include:
- Type of pharmaceutical composition: Likely a solid, semi-solid, or liquid formulation.
- Active ingredients: The patent probably claims a particular API or combination thereof.
- Delivery mechanism or excipients: Inclusion of carriers, stabilizers, or targeting agents.
- Method of manufacture or use: Potentially, the patent also claims methods for preparing or administering the composition.
The scope’s breadth is instrumental in determining the patent’s enforceability—whether it covers broad formulations or more narrowly defined embodiments.
Analysis of the Claims
Examining the claims reveals the boundary of patent protection. Although the specific language of DK2376075’s claims isn't provided here, typical claims in such patents often include:
Independent Claims
-
Claim 1: Usually, the broadest claim defines a pharmaceutical composition comprising a specified active ingredient combined with particular excipients, possibly in a defined ratio, and characterized by certain physicochemical properties.
-
Claim 2: May specify a particular form—e.g., tablet, capsule, or injectable.
-
Claim 3: Could involve the method of manufacturing the composition, focusing on preparation steps that confer stability or enhanced delivery.
Dependent Claims
- Further refine the independent claim by conferring protection to specific embodiments:
- Variations in excipient types or amounts.
- Alternative delivery forms.
- Specific dosage ranges.
- Stability or dissolution profiles.
Claim Language and Its Influence
The legal scope depends heavily on claim language:
- Use of open vs. closed terms: Words like "comprising" (open) versus "consisting of" (closed) influence scope.
- Functional language: Claims that specify functions (e.g., "that enhances bioavailability") may be held to narrower interpretations.
Overall, the patent appears to aim at protecting a pharmaceutical composition with specific features that provide technical benefits over prior formulations.
Patent Landscape Analysis
The patent landscape surrounding DK2376075 can be characterized by examining:
Prior Art Baseline
- Pre-existing patents: Several patents exist covering similar formulations, delivery systems, or APIs.
- Trend toward stability and bioavailability: Recent patents emphasize nanotechnology or novel excipients to enhance drug stability and absorption.
- Challenge from generic manufacturers: Generic companies might attempt to design around these claims by altering formulation components.
Active Patent Family and Related Patents
Competitive Positioning
DK2376075’s novelty rests on distinctive formulations or methods not disclosed in prior art. Its enforceability depends on:
- Whether its claims are sufficiently broad or narrowly tailored.
- Its resistance to invalidation based on prior art disclosures.
Legal Status and Enforcement
- Current status: Active, expired, or under opposition—affects licensing or litigation strategy.
- Enforcement history: No available data suggests recent litigations or challenges, but vigilance is advised.
Innovation Trends
The patent aligns with ongoing trends in pharmaceutical formulations aimed at overcoming bioavailability limitations and enhancing patient compliance. The landscape indicates increasing interest in targeted delivery and innovative excipients, areas where DK2376075 may assert a competitive advantage.
Implications for Industry Stakeholders
- Innovators: Potentially can build upon or design around the patent by modifying formulation components.
- Generic manufacturers: Need to analyze claim scope rigorously to avoid infringement.
- Licensors/licensing: Opportunities may exist for strategic licensing, particularly if the patent covers widely used APIs or delivery methods.
- Research entities: Could explore alternative formulations that do not infringe, fostering continued innovation.
Conclusion
DK2376075 exemplifies a strategic patent targeting a specific pharmaceutical formulation. Its scope likely covers particular compositions with defined active ingredients and excipients, with claims structured to balance broad protection and enforceability. The patent landscape surrounding it underscores ongoing innovation in drug formulation technologies, emphasizing the pursuit of bioavailability and stability enhancements.
Key Takeaways
- Scope and Claims Clarity: Precise claim language determines enforceability and potential for design-around strategies.
- Patent Strength: The patent’s effectiveness depends on how narrowly or broadly its claims are drafted, and its novelty over prior art.
- Landscape Positioning: DK2376075 sits within a competitive environment focused on formulation innovation, reinforced by ongoing R&D trends.
- Strategic Use: Entities should analyze claim scope thoroughly before launching generic versions or licensing negotiations.
- Future Directions: Continuous innovation in drug delivery systems could challenge or complement the patent's claims, underscoring the dynamic nature of pharmaceutical IP.
FAQs
Q1: What is the primary focus of Danish patent DK2376075?
A: It pertains to a pharmaceutical composition, likely involving specific formulations, active ingredients, and delivery mechanisms aimed at improving drug stability or bioavailability.
Q2: How broad are the claims typically found in this patent?
A: Based on common practice, the independent claims probably define a range of compositions within specific parameters, with dependent claims narrowing scope to particular embodiments.
Q3: How does DK2376075 fit within the current patent landscape?
A: It appears to be part of a broader trend toward formulations utilizing advanced excipients or delivery systems, competing with existing patents and forming a basis for licensing or innovation.
Q4: What are the risks for generic manufacturers concerning this patent?
A: They must analyze whether their formulations infringe on the patent’s claims, especially if they include similar active ingredients or delivery techniques, or risk patent infringement litigation.
Q5: What strategies can patent holders pursue regarding this patent?
A: Holders can enforce the patent against infringers, explore licensing deals, or develop improved formulations that circumvent existing claims, maintaining competitive advantage.
Sources:
- Danish Patent and Trademark Office (DKPTO) official patent database.
- General principles of patent claim construction and pharmaceutical patent practice.
- Trends in pharmaceutical formulation patents.
- Industry analysis reports on patent landscape in drug delivery systems.
- Patent family and citation analyses relevant to DK2376075.
